Navigation Links
Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing
Date:9/24/2010

SAN DIEGO, Sept. 24 /PRNewswire/ -- Cylene Pharmaceuticals, Inc. announced today the initiation of a Phase I clinical trial of their first-in-class, oral CK2 inhibitor CX-4945 in patients with multiple myeloma. Cylene also announced the simultaneous closing of a $12 million financing with participation from existing investors including Sanderling Ventures, HBM BioVentures (Cayman) Ltd., Novartis BioVenture Fund, BioVentures Investors, Lilly Ventures, Mitsui & Co. and Morningside Venture Investments Ltd. Proceeds from the financing will be used to expand the human clinical trials program for CX-4945, including the Phase I trial in patients with multiple myeloma and a series of randomized Phase II trials.

The multi-center Phase I study with CX-4945 will be conducted in patients with relapsed or refractory multiple myeloma. The primary objectives of the study are to determine the safety, tolerance and pharmacokinetic (PK) properties of CX-4945 in multiple myeloma patients and to select the appropriate dose for Phase II trials. Secondary objectives are to investigate the pharmacodynamic (PD) activity of CX-4945 using mechanism and tumor-related PD biomarkers that have been validated in both preclinical and clinical studies. In preclinical studies with multiple myeloma cell lines, CX-4945 inhibited critical CK2-mediated events including key signaling pathways and mediators (PI3K/Akt, NFkB, IL-6) that are known to drive the proliferation of multiple myeloma. These findings, coupled with the need for new agents that target molecular pathways shared by all subtypes of multiple myeloma, highlight CX-4945 as a promising therapeutic agent for multiple myeloma.

A separate Phase I clinical trial in patients with solid tumors evaluating CX-4945 as an orally administered single agent has already established favorable pharmacokinetic and safety profiles. Measurement of mechanism and tumor-related biomarkers in patients established that CX-4945 hits the CK2 targ
'/>"/>

SOURCE Cylene Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
2. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
5. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
6. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
7. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
8. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
9. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
10. SenesTech, Inc. Initiates Research Field Trials for ContraPest(R) in Indonesia
11. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  InterMune, Inc. (NASDAQ: ITMN ) ... 2014 financial results at the close of the U.S. ... and webcast will be hosted by InterMune at 4:30 ... investors and others may participate in the conference call ... ID#21728775. A replay of the webcast and teleconference will be ...
(Date:7/28/2014)... Research and Markets has announced the ... report to their offering. ... technique used to determine the size of a particle in ... to analyze the size of particles as it can affect ... performed to determine the behavior and nature of a material, ...
(Date:7/26/2014)... 2014 Canada Endoscopy Visualization Systems ... on the Canada Endoscopy Visualization Systems market. The ... volume (in units) and average prices (in US ... Systems, Mid-Range Endoscopy Visualization Systems and Low-End Endoscopy ... http://www.marketresearchreports.biz/analysis/213254 . , The report also provides company ...
(Date:7/25/2014)... 2014 Amgen (NASDAQ: AMGN ) ... $0.61 per share dividend for the third quarter of ... 2014, to all stockholders of record as of the ... About Amgen Amgen is committed to unlocking the ... by discovering, developing, manufacturing and delivering innovative human therapeutics. ...
Breaking Biology Technology:InterMune to Release Second Quarter Financial Results on August 6 2Global Particle Size Analysis Market 2014-2018 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3
... causes soil to release the potent greenhouse gases methane and ... Nature reveals. "This feedback to our changing atmosphere ... warming as we previously thought," said Dr Kees Jan van ... of Natural Sciences, Trinity College Dublin, and lead author of ...
... fumes could raise the risk of heart attacks, research has ... diesel burns are harmful to blood vessels and can increase ... a heart attack or stroke. The research by the ... on healthy volunteers at levels that would be found in ...
... scale, the tiniest bridge of gold -- that made of ... new research by engineers at the University at Buffalo,s Laboratory ... experiments probing the characteristics of atomic-scale necks of gold that ... pushed into a flat, gold surface. An examination of these ...
Cached Biology Technology:New research reveals soil microbes accelerate global warming 2Diesel fumes pose risk to heart as well as lungs, study shows 2Narrowest bridges of gold are also the strongest, study finds 2
(Date:7/25/2014)... engineering at the University of Houston, has written ... organ development., "Introduction to Tissue Engineering: Applications and ... the field of artificial organ development. Metin Akay, ... UH, served as a series editor on the ... published books on the subject of growing artificial ...
(Date:7/25/2014)... a pleiotropic factor characterized by the existence of ... that confer to the protein deeply different characteristics. ... myelination occurring during development and the different phases ... degeneration, axon regrowth, remyelination and target reinnervation, Researchers ... that the soluble NRG1 upregulation observed in Schwann ...
(Date:7/25/2014)... puberty is influenced by ,imprinted genes,a subset of genes whose ... This is the first evidence that imprinted genes can control ... study were published today in the journal Nature . ... a marker for the timing of puberty in females. ... girls, is an inherited trait, and is linked to breast ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2Could age of first period influence development of diseases in older women? 2
... The world is composed of multiple languages, cultures, races and ... possible that the world is more united through our ears. ... at Case Western Reserve University, proposes that our musical conceptualization ... found the commonality among children of distinct ethnic backgrounds and ...
... 31 May 2011 - Parliamentarians from across the ... today for the 17th EUREKA Inter-Parliamentary Conference. They ... market-oriented R&D projects and to ,fostering a culture ... and Technology Committee head Meir Sheetrit, in the ...
... Adelaide acoustics researchers are investigating the causes of wind ... and solving ,wind turbine syndrome,. They are also ... from wind farms so they can accurately and quickly ... methods. Research leader Dr Con Doolan, of the ...
Cached Biology News:1 world, 1 sound 21 world, 1 sound 3Noise research to combat 'wind turbine syndrome' 2
... scale-up, these culture chambers produce cell yields ... range and are useful alternatives to ... High mechanical • strength and structural integrity ... • Certified nonpyrogenic and sterilized by gamma ...
Rabbit Anti-Mouse Ym1 Polyclonal Antibody,...
Collected at a certified USDA establishment located within the United States. All final processing is done by Quad Five employees....
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (F1676) or contact customer s...
Biology Products: